NTVH - 2023, nummer Special, september 2023
prof. dr. Elias Jabbour
Van meerdere onderzoeken zijn veelbelovende resultaten gerapporteerd over percentages van negatieve minimale restziekte en overleving met ponatinib in combinatie met chemotherapie of chemotherapievrije regimes. Tijdens EHA 2023 presenteerde prof. dr. Elias Jabbour (University of Texas MD Anderson Cancer Center, Houston, Verenigde Staten) de resultaten van de fase III-studie PhALLCON, waarin ponatinib en imatinib in combinatie met chemotherapie met een gereduceerde intensiteit direct werden vergeleken bij nieuw gediagnosticeerde patiënten met Philadelphia-chromosoom positieve acute lymfatische leukemie.1
Lees verderTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
